Physician profile
Thomas E Marshall
NPI 1376571687
$2,228.54
in general payments reported to CMS, 2019-2025
21 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $686 · 2021: $249 · 2022: $105 · 2023: $323 · 2024: $381 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $570.61 | 2019-2020 | |
| New World Medical,INC. | $328.57 | 2023-2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Alcon Vision LLC | $285.76 | 2019-2025 | Rocklatan, Clareon, Total30 |
| Glaukos Corporation | $185.66 | 2020-2025 | Idosetr |
| Ocular Therapeutix, INC. | $117.76 | 2020-2025 | Dextenza |
| Biotissue Holdings INC. | $115.35 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.16 | 2020-2021 | |
| Allergan, INC. | $86.76 | 2020-2021 | |
| Abbvie INC. | $86.60 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $70.25 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $47.71 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $40.73 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $39.37 | 2022 | |
| Mallinckrodt Hospital Products INC. | $29.52 | 2023 | Acthar |
| Coopervision INC. | $28.22 | 2024 | Myday Contact Lens |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $21.42 | 2024 | Infuse |
| Kala Pharmaceuticals, INC. | $18.61 | 2020 | |
| Horizon Therapeutics Plc | $17.39 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $16.62 | 2021 | |
| Sight Sciences, INC. | $16.56 | 2025 | Omni Surgical System |
| Akorn, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.